Last reviewed · How we verify
Haematopoietic growth factor
Haematopoietic growth factors stimulate the bone marrow to produce and release blood cells, including red blood cells, white blood cells, and platelets.
Haematopoietic growth factors stimulate the bone marrow to produce and release blood cells, including red blood cells, white blood cells, and platelets. Used for Chemotherapy-induced neutropenia, Anemia of chronic disease, Bone marrow failure syndromes.
At a glance
| Generic name | Haematopoietic growth factor |
|---|---|
| Also known as | Filgrastim, G-CSF, Pegfilgrastim |
| Sponsor | University College, London |
| Drug class | Hematopoietic growth factor |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
These factors bind to specific receptors on hematopoietic progenitor cells in the bone marrow, triggering proliferation, differentiation, and maturation of blood cell lineages. Common examples include erythropoietin (EPO) for red blood cell production and granulocyte colony-stimulating factor (G-CSF) for white blood cell production. They are used to counteract bone marrow suppression from chemotherapy or to treat various blood disorders.
Approved indications
- Chemotherapy-induced neutropenia
- Anemia of chronic disease
- Bone marrow failure syndromes
Common side effects
- Bone pain
- Fever
- Fatigue
- Headache
- Thrombosis (with EPO)
Key clinical trials
- Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (PHASE3)
- Macrophage Stimulating Factor in the Treatment of Diabetic Wounds (NA)
- Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte) (PHASE1)
- Semaglutide in Auto-HSCT (PHASE2)
- MUK Nine b: OPTIMUM Treatment Protocol (PHASE2)
- Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study) (PHASE3)
- Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) (PHASE4)
- Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Haematopoietic growth factor CI brief — competitive landscape report
- Haematopoietic growth factor updates RSS · CI watch RSS
- University College, London portfolio CI